Back to search results

Developing a New MRI Technique for Brain Tumors After Treatment

This study is developing and testing a new magnetic resonance imaging (MRI) technique called CEST-MRF. The goal is to see if CEST-MRF can help doctors tell the difference between a brain tumor growing worse and changes in the tumor caused by radiation treatment (stereotactic radiosurgery or SRS). Researchers will measure changes in CEST-MRF parameters over time. This is an observational study, meaning participants will be monitored without receiving a specific treatment from the study. The study aims to enroll 119 participants, including healthy volunteers and patients aged 18 and older with metastatic brain tumors (brain cancer that has spread from another part of the body). The study's status is currently unclear.

Study design
This is an observational study with a planned enrollment of 119 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in CEST-MRF parameters for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05559853

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~119 participants
Updated 2026-03-06 on ClinicalTrials.gov
What's tested:CEST-MRF

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion
Measured over Up to 3 years

Conditions

Brain Metastases
Brain Metastases, Adult
Metastatic Brain Tumor
Metastatic Brain Cancer

Explore related trials

Healthy VolunteersMetastatic Malignant Neoplasm in the Brain

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Ouri Cohen, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Ouri Cohen, PhD
[email protected]
646-608-8259
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Able to understand and give informed consent
No known cancer diagnosis
Age ≥ 18 years
Able to understand and give informed consent
At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
Age ≥ 18 years
Able to understand and give informed consent
At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
Planned SRS treatment

Exclusion

Pregnant or breastfeeding women
Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
Age \< 18 years

What this trial measures

  • Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motionUp to 3 years

    Develop a rapid and robust 3D CEST-MRF pulse sequence for clinical scanners using our preclinical CEST-MRF pulse sequence as a basis by evaluating the changes of the 6 CEST-MRF parameters with and without motion. These parameters include the water T1 and T2 relaxation (T1w,T2w), amide exchange rate (ksw) and volume fraction (fs) and the semi-solid exchange rate (kssw) and volume fraction (fss).